Anzeige
Mehr »
Login
Freitag, 22.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J2CW | ISIN: US4626292050 | Ticker-Symbol: I7G0
Siehe auch IPSEN SA
Frankfurt
21.11.24
08:01 Uhr
26,400 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
IPSEN SA ADR Chart 1 Jahr
5-Tage-Chart
IPSEN SA ADR 5-Tage-Chart

Aktuelle News zur IPSEN SA ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoIpsen Pharma: Bylvay (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS308Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today...
► Artikel lesen
15.11.Ipsen Pharma: Iqirvo (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus317Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 2024...
► Artikel lesen
07.11.Ipsen Pharma: Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital1
24.10.Ipsen's Iqirvo recommended by NICE to treat rare liver disease primary biliary cholangitis1
23.10.Ipsen Q3 Sales Increase; Lifts FY24 Outlook3
23.10.Ipsen S.A. reports Q3 results; raises FY24 guidance2
IPSEN SA ADR Aktie jetzt für 0€ handeln
23.10.Ipsen Pharma: Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance252PARIS, FRANCE, 23 October 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its performance for the year to date and the third quarter of 2024. ...
► Artikel lesen
14.10.Ipsen Pharma: Ipsen receives its second Shingo Prize for operational excellence252Ipsen is the first pharma company in the world to receive Shingo Prizes for two sites producing treatments for patientsIpsen's first Shingo Prize was received by its production site in Signes, France...
► Artikel lesen
09.10.Ipsen Pharma: Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital2
09.10.Ipsen's Iqirvo approved by MHRA to treat primary biliary cholangitis in adults6
09.10.Ipsen's Elafibranor gains MHRA approval for PBC treatment1
03.10.Eton Pharma To Buy SPIGFD Drug Increlex From Ipsen1
03.10.Eton Pharmaceuticals to buy Increlex product from Ipsen1
03.10.Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen3
02.10.DelveInsight Business Research, LLP: Ipsen's IQIRVO Approval Has Intensified the Primary Biliary Cholangitis Market Space | DelveInsight428The European Commission has granted conditional approval for Ipsen's IQIRVO (elafibranor) for the treatment of primary biliary cholangitis in adults, marking the first new therapy for this...
► Artikel lesen
30.09.Ipsen's Kayfanda granted EC approval to treat cholestatic pruritus in Alagille syndrome1
24.09.Citi maintains Buy rating on Ipsen shares with consistent price target4
24.09.Ipsen's Iqirvo receives EC approval to treat primary biliary cholangitis in adults3
24.09.Ipsen crosses EU finish line with Alagille syndrome drug1
23.09.Ipsen's Iqirvo wins European approval for primary biliary cholangitis2
Seite:  Weiter >>
114 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1